

General Assembly

February Session, 2020

Raised Bill No. 5295



Referred to Committee on GENERAL LAW

Introduced by: (GL)

AN ACT CONCERNING REVISIONS TO MEDICAL MARIJUANA STATUTES.

Be it enacted by the Senate and House of Representatives in General Assembly convened:

Section 1. Subsection (b) of section 21a-408d of the general statutes is
 repealed and the following is substituted in lieu thereof (*Effective October* 1, 2020):

4 (b) (1) The qualifying patient, or, if the qualifying patient is under 5 eighteen years of age and not an emancipated minor, the custodial 6 parent, guardian or other person having legal custody of the qualifying 7 patient, shall select a licensed, in-state dispensary to obtain the palliative 8 marijuana products at the time of registration. Upon the issuance of the 9 certificate of registration by the department, the qualifying patient, or 10 the qualifying patient's custodial parent, guardian or other person 11 having legal custody of the qualifying patient, shall purchase such 12 palliative marijuana products from such dispensary, except that the 13 qualifying patient, or the qualifying patient's custodial parent, guardian 14 or other person having legal custody of the qualifying patient, may 15 change such dispensary in accordance with regulations adopted by the

department. Any person with a valid registration certificate who is
found to be in possession of marijuana that did not originate from the
selected dispensary may be subject to hearing before the commissioner
for possible enforcement action concerning the registration certificate
issued by the department.

21 (2) The provisions of subdivision (1) of this subsection shall not apply 22 if the qualifying patient, or the qualifying patient's custodial parent, 23 guardian or other person having legal custody of the qualifying patient 24 chooses to purchase such palliative marijuana from a dispensary that 25 has more than one location, provided the dispensary at which the 26 purchase is made has real-time integration with the electronic 27 prescription drug monitoring program established pursuant to section 28 21a-254.

Sec. 2. Subsection (a) of section 21a-408d of the general statutes is
repealed and the following is substituted in lieu thereof (*Effective October*1, 2020):

32 (a) Each qualifying patient who is issued a written certification for the 33 palliative use of marijuana under subdivision (1) of subsection (a) of 34 section 21a-408a, and the primary caregiver of such qualifying patient, 35 shall register with the Department of Consumer Protection. Such 36 registration shall be effective from the date the Department of 37 Consumer Protection issues a certificate of registration until the 38 expiration of the written certification issued by the physician or 39 advanced practice registered nurse. The qualifying patient and the 40 primary caregiver shall provide sufficient identifying information, as 41 determined by the department, to establish the personal identity of the 42 qualifying patient and the primary caregiver. If the qualifying patient is 43 under eighteen years of age and not an emancipated minor, the 44 custodial parent, guardian or other person having legal custody of the 45 qualifying patient shall also provide a letter from both the qualifying 46 patient's primary care provider and a physician who is board certified 47 in an area of medicine involved in the treatment of the debilitating

48 condition for which the qualifying patient was certified that confirms 49 that the palliative use of marijuana is in the best interest of the qualifying 50 patient. A physician may issue a written certification for the palliative 51 use of marijuana by a qualifying patient who is under eighteen years of 52 age, provided such written certification shall not be for marijuana in a 53 dosage form that requires that the marijuana be smoked, inhaled or 54 vaporized. The qualifying patient or the primary caregiver shall report 55 any change in the identifying information to the department not later 56 than five business days after such change. The department shall issue a 57 registration certificate to the qualifying patient and to the primary 58 caregiver [and may charge a reasonable fee, not to exceed twenty-five 59 dollars, for each registration certificate issued under this subsection at 60 <u>no charge</u>. [Any registration fees collected by the department under this 61 subsection shall be paid to the State Treasurer and credited to the 62 General Fund.]

63 Sec. 3. (NEW) (Effective from passage) The Commissioner of Consumer 64 Protection shall cease charging the nonrefundable fee for administrative 65 costs for each qualifying patient and the nonrefundable application fee 66 for each qualifying patient and caregiver under chapter 420f of the 67 general statutes. The commissioner shall also cease charging the 68 renewal fee for each qualifying patient under chapter 420f of the general 69 statutes. The commissioner shall amend existing regulations to 70 eliminate such fees in accordance with the provisions of this section.

Sec. 4. Section 21a-408m of the general statutes is repealed and the
following is substituted in lieu thereof (*Effective October 1, 2020*):

(a) The Commissioner of Consumer Protection may adopt
regulations, in accordance with chapter 54, to establish (1) a standard
form for written certifications for the palliative use of marijuana issued
by physicians and advanced practice registered nurses under
subdivision (1) of subsection (a) of section 21a-408a, and (2) procedures
for registrations under section 21a-408d, as amended by this act. Such
regulations, if any, shall be adopted after consultation with the Board of

80 Physicians established in section 21a-408*l*.

81 The Commissioner of Consumer Protection shall adopt (b) 82 regulations, in accordance with chapter 54, to establish a reasonable fee 83 to be collected from each qualifying patient to whom a written 84 certification for the palliative use of marijuana is issued under 85 subdivision (1) of subsection (a) of section 21a-408a, for the purpose of 86 offsetting the direct and indirect costs of administering the provisions 87 of sections 21a-408 to 21a-408n, inclusive. The commissioner shall collect 88 such fee at the time the qualifying patient registers with the Department 89 of Consumer Protection under subsection (a) of section 21a-408d. Such 90 fee shall be in addition to any registration fee that may be charged under 91 said subsection. The fees required to be collected by the commissioner 92 from qualifying patients under this subsection shall be paid to the State 93 Treasurer and credited to the General Fund.]

94 [(c)] (b) The Commissioner of Consumer Protection shall adopt 95 regulations, in accordance with chapter 54, to implement the provisions 96 of sections 21a-408 to 21a-408g, inclusive, <u>as amended by this act</u>, and 97 section 21a-408*l*. At a minimum, such regulations shall:

98 (1) Govern the manner in which the department considers
99 applications for the issuance and renewal of registration certificates for
100 qualifying patients and primary caregivers, and establish any additional
101 information to be contained in such registration certificates;

(2) Define the protocols for determining the amount of usable
marijuana that is necessary to constitute an adequate supply to ensure
uninterrupted availability for a period of one month, including amounts
for topical treatments;

(3) Establish criteria for adding medical conditions, medical
treatments or diseases to the list of debilitating medical conditions that
qualify for the palliative use of marijuana;

109 (4) Establish a petition process under which members of the public

110 may submit petitions, in such manner and in such form as prescribed in 111 the regulations, regarding the addition of medical conditions, medical 112 treatments or diseases to the list of debilitating medical conditions; 113 (5) Establish a process for public comment and public hearings before 114 the board regarding the addition of medical conditions, medical 115 treatments or diseases to the list of debilitating medical conditions, 116 medical treatments or diseases; 117 (6) Add additional medical conditions, medical treatments or 118 diseases to the list of debilitating medical conditions that qualify for the 119 palliative use of marijuana as recommended by the board; and 120 (7) Develop a distribution system for marijuana for palliative use that 121 provides for: 122 (A) Marijuana production facilities within this state that are housed 123 on secured grounds and operated by licensed producers; and 124 (B) Distribution of marijuana for palliative use to qualifying patients 125 or their primary caregivers by licensed dispensaries. 126 [(d) The commissioner shall submit regulations pursuant to 127 subsections (b) and (c) of this section to the standing legislative 128 regulation review committee not later than July 1, 2013.] 129 Sec. 5. Section 21a-408 of the general statutes is repealed and the 130 following is substituted in lieu thereof (*Effective October 1, 2020*): 131 As used in this section, sections 21a-408a to 21a-408o, inclusive, and 132 sections 21a-408r to 21a-408v, inclusive, unless the context otherwise 133 requires: 134 (1) "Advanced practice registered nurse" means an advanced practice 135 registered nurse licensed pursuant to chapter 378; 136 (2) "Cultivation" includes planting, propagating, cultivating, growing

137 and harvesting;

138 (3) "Debilitating medical condition" means (A) cancer, glaucoma, 139 positive status for human immunodeficiency virus or acquired immune 140 deficiency syndrome, Parkinson's disease, multiple sclerosis, damage to 141 the nervous tissue of the spinal cord with objective neurological 142 indication of intractable spasticity, epilepsy or uncontrolled intractable 143 seizure disorder, cachexia, wasting syndrome, Crohn's disease, 144 posttraumatic stress disorder, irreversible spinal cord injury with 145 objective neurological indication of intractable spasticity, cerebral palsy, 146 cystic fibrosis, [or] terminal illness requiring end-of-life care, chronic 147 pain of at least six months duration associated with a specified 148 underlying chronic condition refractory to other treatment intervention, 149 and Ehlers-Danlos syndrome associated with chronic pain, except, if the 150 qualifying patient is under eighteen years of age, "debilitating medical 151 condition" means terminal illness requiring end-of-life care, irreversible 152 spinal cord injury with objective neurological indication of intractable 153 spasticity, cerebral palsy, cystic fibrosis, severe epilepsy or uncontrolled 154 intractable seizure disorder, or (B) any medical condition, medical 155 treatment or disease approved for qualifying patients by the 156 Department of Consumer Protection pursuant to regulations adopted 157 under section 21a-408m, as amended by this act;

(4) "Institutional animal care and use committee" means a committee
that oversees an organization's animal program, facilities and
procedures to ensure compliance with federal policies, guidelines and
principles related to the care and use of animals in research;

(5) "Institutional review board" means a specifically constituted
review body established or designated by an organization to protect the
rights and welfare of persons recruited to participate in biomedical,
behavioral or social science research;

(6) "Laboratory" means a laboratory located in the state that islicensed to provide analysis of controlled substances pursuant to section

168 21a-246 and section 21a-408r;

(7) "Laboratory employee" means a person who is (A) licensed as a
laboratory employee pursuant to section 21a-408r, or (B) holds a
temporary certificate of registration issued pursuant to section 21a-408r;

(8) "Licensed dispensary" or "dispensary" means a person who islicensed as a dispensary pursuant to section 21a-408h;

(9) "Licensed producer" or "producer" means a person who is licensedas a producer pursuant to section 21a-408i;

176 (10) "Marijuana" means marijuana, as defined in section 21a-240;

(11) "Nurse" means a person who is licensed as a nurse under chapter378;

179 (12) "Palliative use" means the acquisition, distribution, transfer, 180 possession, use or transportation of marijuana or paraphernalia relating 181 to marijuana, including the transfer of marijuana and paraphernalia 182 relating to marijuana from the patient's primary caregiver to the 183 qualifying patient, to alleviate a qualifying patient's symptoms of a 184 debilitating medical condition or the effects of such symptoms, but does 185 not include any such use of marijuana by any person other than the 186 qualifying patient;

187 (13) "Paraphernalia" means drug paraphernalia, as defined in section188 21a-240;

(14) "Physician" means a person who is licensed as a physician under
chapter 370, but does not include a physician assistant, as defined in
section 20-12a;

(15) "Primary caregiver" means a person, other than the qualifying
patient and the qualifying patient's physician or advanced practice
registered nurse, who is eighteen years of age or older and has agreed
to undertake responsibility for managing the well-being of the

7 of 9

196 qualifying patient with respect to the palliative use of marijuana, 197 provided (A) in the case of a qualifying patient (i) under eighteen years 198 of age and not an emancipated minor, or (ii) otherwise lacking legal 199 capacity, such person shall be a parent, guardian or person having legal 200 custody of such qualifying patient, and (B) in the case of a qualifying 201 patient eighteen years of age or older or an emancipated minor, the need 202 for such person shall be evaluated by the qualifying patient's physician 203 or advanced practice registered nurse and such need shall be 204 documented in the written certification;

205 (16) "Qualifying patient" means a person who: (A) Is a resident of 206 Connecticut, (B) has been diagnosed by a physician or an advanced 207 practice registered nurse as having a debilitating medical condition, and 208 (C) (i) is eighteen years of age or older, (ii) is an emancipated minor, or 209 (iii) has written consent from a custodial parent, guardian or other 210 person having legal custody of such person that indicates that such 211 person has permission from such parent, guardian or other person for 212 the palliative use of marijuana for a debilitating medical condition and 213 that such parent, guardian or other person will (I) serve as a primary 214 caregiver for the qualifying patient, and (II) control the acquisition and 215 possession of marijuana and any related paraphernalia for palliative use 216 on behalf of such person. "Qualifying patient" does not include an 217 inmate confined in a correctional institution or facility under the supervision of the Department of Correction; 218

(17) "Research program" means a study approved by the Department
of Consumer Protection in accordance with this chapter and undertaken
to increase information or knowledge regarding the growth, processing,
medical attributes, dosage forms, administration or use of marijuana to
treat or alleviate symptoms of any medical conditions or the effects of
such symptoms;

(18) "Research program employee" means a person who (A) is
licensed as a research program employee under section 21a-408t, or (B)
holds a temporary certificate of registration issued pursuant to section

228 21a-408t;

(19) "Research program subject" means a person registered as a
research program subject pursuant to section 21a-408v;

(20) "Usable marijuana" means the dried leaves and flowers of the
marijuana plant, and any mixtures or preparations of such leaves and
flowers, that are appropriate for the palliative use of marijuana, but does
not include the seeds, stalks and roots of the marijuana plant; and

(21) "Written certification" means a written certification issued by a
physician or an advanced practice registered nurse pursuant to section
21a-408c.

Sec. 6. (NEW) (*Effective October 1, 2020*) No producer licensed pursuant to section 21a-408i of the general statutes, or any agent of such producer, shall offer or give to a dispensary licensed pursuant to section 21a-408h of the general statutes, or any employee of such dispensary, anything of value, including, but not limited to, a gift or reward, unless authorized by law.

This act shall take effect as follows and shall amend the following sections:		
Section 1	October 1, 2020	21a-408d(b)
Sec. 2	October 1, 2020	21a-408d(a)
Sec. 3	from passage	New section
Sec. 4	October 1, 2020	21a-408m
Sec. 5	October 1, 2020	21a-408
Sec. 6	October 1, 2020	New section

Statement of Purpose:

To make various revisions to the medical marijuana program.

[Proposed deletions are enclosed in brackets. Proposed additions are indicated by underline, except that when the entire text of a bill or resolution or a section of a bill or resolution is new, it is not underlined.]